Mitoxantrone

Generic Name: Mitoxantrone

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₈N_₄O_₆

CAS Number: 65271-80-9

Unique Ingredient Identifier: BZ114NVM5P

Background: An anthracenedione-derived antineoplastic agent.

Indication: For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma

Associated Therapies: Autologous hematopoietic stem cell transplant

Clinical Trials

Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Diffuse Large B-Cell Lymphoma
POOR PROGNOSIS

Interventions: Drug: Rituximab
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Prednisone
Drug: Granulocyte-colony-stimulating factor
Drug: Mitoxantrone
Drug: Cytarabine ARA-C
Drug: Dexamethasone
Drug: Carmustine BCNU
Drug: Etoposide
Drug: Melphalan
Radiation: Radiotherapy
Procedure: PBSC reinfusion

First Posted Date: 2007-11-09

Last Posted Date: 2007-11-09

Lead Sponsor: Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie

Target Recruit Count: 94

Registration Number: NCT00556127

Locations: 🇮🇹
Centro Trapianti Midollo Osseo, P.O. Businco, Cagliari, Italy
🇮🇹
Ospedale S. Gerardo, Monza, Italy
🇮🇹
Osp. maggiore della Carità, Novara, Italy

and more 11 locations

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Phase 4

Completed

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2007-09-10

Last Posted Date: 2010-01-05

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 100

Registration Number: NCT00526305

Locations: 🇪🇸
Hospital General de Segovia, Segovia, Spain
🇪🇸
Hospital Universitario de Canarias, Tenerife, Spain
🇪🇸
H.U. Virgen del Rocio, Sevilla, Spain

and more 46 locations

AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: AMD3100
Drug: Mitoxantrone
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2007-08-07

Last Posted Date: 2016-12-12

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 52

Registration Number: NCT00512252

Locations: 🇺🇸
Washington University, St. Louis, Missouri, United States

Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma

Phase 2

Terminated

Conditions: Lymphoma, Follicular

Interventions: Drug: Bortezomib
Drug: Rituximab
Drug: Fludarabine
Drug: Mitoxantrone
Drug: Dexamethasone

First Posted Date: 2007-08-02

Last Posted Date: 2014-05-12

Lead Sponsor: Duke University

Target Recruit Count: 14

Registration Number: NCT00510887

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma

Phase 3

Conditions: Diffuse Large B-Cell Lymphoma
IPI≥2

Interventions: Drug: Rituximab
Drug: Vincristina
Drug: Ciclofosfamide
Drug: Prednisone
Drug: Doxorubicina
Drug: Pegfilgrastim
Drug: Mitoxantrone
Drug: ARA-C
Drug: Lenograstim
Drug: BCNU
Drug: VP-16
Procedure: ASCT

First Posted Date: 2007-07-11

Last Posted Date: 2011-02-15

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 399

Registration Number: NCT00499018

Locations: 🇮🇹
Istituto Vito Fazzi, Lecce, Italy
🇮🇹
Ospedale Umberto I - DH Oncoematologico, Nocera Inferiore, Salerno, Italy
🇮🇹
Az. Osp. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

and more 71 locations

Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer

Phase 2

Terminated

Conditions: Prostatic Neoplasms

Interventions: Drug: Mitoxantrone
Drug: GM-CSF

First Posted Date: 2007-05-22

Last Posted Date: 2017-11-29

Lead Sponsor: Stanford University

Target Recruit Count: 10

Registration Number: NCT00477087

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia

Phase 1

Completed

Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)

Interventions: Drug: alvocidib
Drug: cytarabine
Drug: mitoxantrone hydrochloride
Other: pharmacological study

First Posted Date: 2007-05-07

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00470197

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)

Phase 2

Terminated

Conditions: Metastatic Prostate Cancer

First Posted Date: 2007-03-27

Last Posted Date: 2011-09-16

Lead Sponsor: Accelerated Community Oncology Research Network

Target Recruit Count: 22

Registration Number: NCT00452387

Locations: 🇺🇸
Hematology Oncology Centers of the Northern Rockies, PC, Billings, Montana, United States
🇺🇸
The West Clinic, Memphis, Tennessee, United States
🇺🇸
Lancaster Cancer Center, Lancaster, Pennsylvania, United States

and more 7 locations